Subscribe To
ZYME / Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
ZYME News
By GlobeNewsWire
November 1, 2023
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal
By GlobeNewsWire
October 17, 2023
Zymeworks To Host Third Quarter 2023 Results Conference Call
VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal
By Seeking Alpha
September 11, 2023
Adding Zymeworks To My Value Watchlist (Initial Buy Rating)
Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results i more_horizontal
By Seeking Alpha
August 10, 2023
Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communication more_horizontal
By Zacks Investment Research
August 10, 2023
Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss more_horizontal
By GlobeNewsWire
July 3, 2023
Zymeworks Announces Participation in Upcoming Investor Conference
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal
By GlobeNewsWire
June 1, 2023
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal
By Seeking Alpha
May 8, 2023
Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kenneth Galbraith - Chairman, Chief Executi more_horizontal